- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00454831
Efficacy and Safety of HEP-40 Chitosan for Mild to Moderately Elevated Cholesterol (HEP-40)
A 16 Week With 12 Week Active Treatment Multi-Center, Placebo-Controlled, Randomized Study Evaluating the Efficacy of HEP-40 Chitosan in Managing Moderate Hypercholesterolemia
Chitosan is a natural product that is produced commercially through the deacetylation of chitin, which is found in the exoskeleton of crustaceans. It has been suggested that chitosan has a lipid-lowering effect.
This study was designed to determine if HEP-40 chitosan (Enzymatic Polychitosamine Hydrolysate - 40kDa), a short-chained chitosan with a molecular weight of 40 kDa, is safe and effective in lowering LDL-cholesterol levels in patients with mild to moderately elevated cholesterol levels and who have not been previously treated with other lipid-lowering agents.
Study Overview
Detailed Description
Chitosan is a natural product that is produced commercially through the deacetylation of chitin, which is found in the exoskeleton of crustaceans. It has been suggested that chitosan has a lipid-lowering effect by binding to fatty acids and cholesterol in the gastrointestinal tract and restricting their absorption.
This study was designed to determine if HEP-40 chitosan (Enzymatic Polychitosamine Hydrolysate - 40kDa), a short-chained chitosan with a molecular weight of 40 kDa, is safe and effective in lowering LDL-cholesterol levels in patients who have not been previously treated with lipid-lowering agents and who have cholesterol levels that are mild to moderately above the levels recommended by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines.
This is a multi-centre, randomized, double-blind, placebo-controlled study. Following a 4-week Pre-Randomization Phase where patients will be instructed to maintain a stable diet, patients will be randomized to one of the following study groups for a 12-week Active Treatment Phase:
- HEP-40 400 mg three times a day (400 mg TID)
- HEP-40 800 mg twice a day (800 mg BID)
- HEP-40 800 mg three times a day (800 mg TID)
- HEP-40 2400 mg once a day (2400 mg QD)
- Placebo, three times a day (placebo)
The primary objective is to evaluate the clinical benefit of administering HEP-40 chitosan at different doses and at different dosing regimens compared with placebo. Clinical benefit will be defined as the reduction in LDL-cholesterol after 4 weeks of active treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Quebec
-
Westmount, Quebec, Canada, H3Z 1R7
- JSS Medical Research Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosed with borderline, mild or moderate hypercholesterolemia, defined as LDL-C levels between 2.0 mmol/L and 4.5 mmol/L;
- At low (≤10%) or moderate (11-19%) 10-year risk for cardiovascular disease according to the Framingham model;
- Treatment-naïve for any lipid-lowering medications including statins, other pharmaceuticals or nutraceuticals;
- Stable diet and willing to continue on the dietary regimen recommended by their physician (NCEP Step 1 Diet) for the duration of the study;
- Woman of child bearing potential must be practicing effective birth control for a period of at least one month prior to initiation of the study.
Exclusion Criteria:
- Any concomitant condition which in the opinion of the investigator would preclude the patient from successfully participating in the study;
- Pregnant or that are breast feeding;
- Participation in another clinical trial within 30 days from initiation of the study;
- Known cardiac disease including: congestive heart failure, cardiac arrhythmias, unstable angina, myocardial infarction within the last 6 months, or uncontrolled malignant hypertension;
- High risk of developing coronary artery disease;
- Any condition affecting a major organ system, such as liver or kidney disease or malignancy;
- Uncontrolled diabetes mellitus or newly diagnosed patients (within 3 months) or recent change in anti-diabetic pharmacotherapy within 3 months of screening;
- Evidence of active renal disease indicated by serum creatinine > 2.0 mg/dL;
- Known HIV or Hepatitis B or C positive;
- Concurrent use of corticosteroids;
- Allergy or intolerance to crustaceans and/or seafood products.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: HEP 400mg TID
HEP-40 400 mg three times a day
|
Enzymatically Hydrolyzed Polychitosamine-40 kDa
Other Names:
|
Active Comparator: HEP 800mg BID
HEP-40 800 mg twice a day
|
Enzymatically Hydrolyzed Polychitosamine-40 kDa
Other Names:
|
Active Comparator: HEP 800mg TID
HEP-40 800 mg three times a day
|
Enzymatically Hydrolyzed Polychitosamine-40 kDa
Other Names:
|
Active Comparator: HEP 2400mg QD
HEP-40 2400 mg once a day
|
Enzymatically Hydrolyzed Polychitosamine-40 kDa
Other Names:
|
Placebo Comparator: Placebo
Placebo, three times a day
|
Enzymatically Hydrolyzed Polychitosamine-40 kDa
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent change in serum LDL-C between the baseline and 4-week visit compared to placebo.
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent change in serum LDL-C from baseline to 8- and 12-weeks of treatment compared to placebo
Time Frame: 12 weeks
|
12 weeks
|
Percent change in serum total cholesterol from baseline to 12 weeks of treatment compared to placebo
Time Frame: 12 weeks
|
12 weeks
|
Percent change in serum HDL-C from baseline to 12 weeks of treatment compared to placebo
Time Frame: 12 weeks
|
12 weeks
|
Percent change in serum triglycerides from baseline to 12 weeks of treatment compared to placebo
Time Frame: 12 weeks
|
12 weeks
|
Safety and tolerability over the 12-week active treatment period, as determined by treatment-emergent adverse events.
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jacques HF Lenis, MD, Recherche Invascor Inc
- Study Director: John S Sampalis, PhD, JSS Medical Research Inc.
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 153-PTL-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypercholesterolemia
-
National Medical Research Center for Therapy and...Moscow State University of Medicine and DentistryRecruitingMedication Adherence | Adherence, Medication | Treatment Adherence | Familial Hypercholesterolemia | Motivational Interviewing | Adherence, Patient | Treatment Adherence and Compliance | Patient Compliance | Adherence | Hypercholesterolemia, Familial | Patient Adherence | Hypercholesterolemia, Autosomal Dominant and other conditionsRussian Federation
-
Direct PlantesUnknownHYPERCHOLESTEROLEMIAFrance
-
Chong Kun Dang PharmaceuticalRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Addpharma Inc.CompletedPrimary HypercholesterolemiaKorea, Republic of
-
JW PharmaceuticalCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Provident Clinical ResearchGlaxoSmithKlineUnknownPrimary HypercholesterolemiaUnited States
-
Organon and CoCompletedPrimary Hypercholesterolemia | Homozygous Familial Hypercholesterolemia
-
Boryung Pharmaceutical Co., LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Ahn-Gook Pharmaceuticals Co.,LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
Clinical Trials on HEP-40 chitosan
-
University of OxfordCancer Institute and Hospital, Chinese Academy of Medical Sciences; Qidong... and other collaboratorsCompletedLiver Diseases | Hepatitis B | Liver NeoplasmsUnited Kingdom, China
-
Loyola UniversityColumbia UniversityRecruitingInflammation | Stress | RacismUnited States
-
Inmunotek S.L.CompletedImmune System DiseasesSpain
-
Istanbul University - Cerrahpasa (IUC)CompletedInvestigation of the Effectiveness of Environmental Enrichment-Based Intervention in Preterm InfantsDevelopment, Infant | Therapy | Preterm | MotorTurkey
-
University of Wisconsin, MadisonNational Center for Complementary and Integrative Health (NCCIH)CompletedMental Health | HealthUnited States
-
Lawson Health Research InstituteTerminated
-
Denver Nephrologists, P.C.CM&D Pharma LimitedCompletedChronic Kidney DiseaseUnited States
-
Lady Davis InstituteMcGill University Health Centre/Research Institute of the McGill University... and other collaboratorsCompletedDepression | Anxiety | Renal DiseaseCanada
-
Caspar WohlfahrtDr Caspar Wohlfahrt; Dr Maria BaltaRecruitingPeriodontitis | Periodontal Diseases | Periodontal Pocket | Periodontal InflammationNorway